Skip to content

Identifying Required Avidity for Safe and Efficacious Bispecifics

Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions, but introduce non-trivial drug design parameters that must be considered as part of target selection and lead identification. Applied BioMath Assess™ Avidity model pack supports early feasibility assessment for bispecific modalities. This case study demonstrates how to use Assess to identify the level of avidity required for a drug to have a favorable efficacy and therapeutic index.

To follow along in this case study, you will need to download the associated save file.